Tag: PAH

Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension

– The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance – – The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, including amino-terminal brain natriuretic propeptide (NT-proBNP), and World Health Organization (WHO) […]

Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary […]

Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress

BASEL, Switzerland and DURHAM, N.C., Jan. 31, 2019 /PRNewswire/ — Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension (PAH) and other indications, will present its latest nonclinical and clinical data at the Pulmonary Vascular Research Institute (PVRI) 13th Annual World Congress on Pulmonary Vascular Disease, […]

Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag

SAN DIEGO, Jan. 24, 2019 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH).  The global license […]

Medtronic Receives FDA Approval for Implantable System for Remodulin® to Treat Patients with Pulmonary Arterial Hypertension

DUBLIN – July 31, 2018 – Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for the Implantable System for Remodulin® (ISR) to treat patients with pulmonary arterial hypertension (PAH). Through a first-of-its-kind collaboration, the Medtronic SynchroMed(TM) II drug delivery system and cardiac catheter technologies were leveraged to […]